MyPath: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients

MyPath:为癌症患者开发和实施以患者为中心的创新护理途径

基本信息

  • 批准号:
    10059023
  • 负责人:
  • 金额:
    $ 70.31万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    EU-Funded
  • 财政年份:
    2022
  • 资助国家:
    英国
  • 起止时间:
    2022 至 无数据
  • 项目状态:
    未结题

项目摘要

In the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancerIn the EU, 2.7M people were diagnosed with and 1.3M died of cancer in 2020. Over 12M people have survived cancer, thanks to advances in early detection and new therapies. With higher cure rates and more patients living longer with cancer, access to patient-centred care consisting of optimal supportive, palliative, survivorship and end-of-life care becomes increasingly important. However, cancer care still has silos, and to this day, there is no technical support available that is suitable for different cultures, settings and environments. Several randomised controlled trials have provided evidence that the integration of patient-centred care in standard oncology care results in better patient and caregiver outcomes. As yet, these findings have not translated into clinical routine. In this project, we will develop technology-enhanced and evidence-based patient-centred care pathways, called MyPath, to be merged with tumour-centred treatments across supportive, palliative, survivorship and end-of-life care. In the UK we already have experience of the integration of cancer pain assessment and management pathway in 19 regional cancer centres within the context of a randomised controlled trial. The outcome of this was positive and demonstrated that the use of simple, consistent and clear language used by clinicians when speaking with all patients, can transform care in a very positive way. While MyPath is a complex study, what we aim to achieve with simple consistent and clear pathways is not at all complicated and should lead to much improved care and equity of care for cancer patients. MyPath integrates patient-reported outcomes of the OUS Eir software, to be further advanced with contributions of renowned European oncologists, ethicists, psychologists and sociologists. It will be configurated on the eHealth platform of our SME partner DNV Imatis. Its effectiveness and sustainability will be assessed in an implementation science study in 9 clinical centres across Europe. With the support of leading cancer care professional associations ESMO and EAPC, and the cancer patient organisation ECPC, we are committed to delivering the right care to the right person at the right time by the right persons. We hypothesise that MyPath can significantly improve the quality of and access to treatment and care, reduce variations in clinical practice, and optimise resources in family, community, and hospital care settings. This will ultimately reduce the physical, emotional, and ultimately economic burden linked to cancer
在欧盟,2020年有270万人被诊断患有癌症,130万人死于癌症。由于早期检测和新疗法的进步,超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长,获得以患者为中心的护理,包括最佳支持、姑息治疗、生存和临终关怀,变得越来越重要。然而,癌症治疗仍然存在孤岛,直到今天,还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据,证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止,这些发现还没有转化为临床常规。在这个项目中,我们将开发技术增强和基于证据的以患者为中心的护理途径,称为MyPath,将其与肿瘤为中心的治疗相结合,包括支持性、姑息性、生存和临终关怀。在英国,我们已经在随机对照试验的背景下,在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的,并证明了临床医生在与所有患者交谈时使用简单,一致和清晰的语言,可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究,但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂,应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果,并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下,我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性,减少临床实践中的变化,并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟,2020年有270万人被诊断出患有癌症,130万人死于癌症。由于早期检测和新疗法的进步,超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长,获得以患者为中心的护理,包括最佳支持、姑息治疗、生存和临终关怀,变得越来越重要。然而,癌症治疗仍然存在孤岛,直到今天,还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据,证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止,这些发现还没有转化为临床常规。在这个项目中,我们将开发技术增强和基于证据的以患者为中心的护理途径,称为MyPath,将其与肿瘤为中心的治疗相结合,包括支持性、姑息性、生存和临终关怀。在英国,我们已经在随机对照试验的背景下,在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的,并证明了临床医生在与所有患者交谈时使用简单,一致和清晰的语言,可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究,但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂,应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果,并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下,我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性,减少临床实践中的变化,并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟,2020年有270万人被诊断出患有癌症,130万人死于癌症。由于早期检测和新疗法的进步,超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长,获得以患者为中心的护理,包括最佳支持、姑息治疗、生存和临终关怀,变得越来越重要。然而,癌症治疗仍然存在孤岛,直到今天,还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据,证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止,这些发现还没有转化为临床常规。在这个项目中,我们将开发技术增强和基于证据的以患者为中心的护理途径,称为MyPath,将其与肿瘤为中心的治疗相结合,包括支持性、姑息性、生存和临终关怀。在英国,我们已经在随机对照试验的背景下,在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的,并证明了临床医生在与所有患者交谈时使用简单,一致和清晰的语言,可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究,但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂,应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果,并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下,我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性,减少临床实践中的变化,并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟,2020年有270万人被诊断出患有癌症,130万人死于癌症。由于早期检测和新疗法的进步,超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长,获得以患者为中心的护理,包括最佳支持、姑息治疗、生存和临终关怀,变得越来越重要。然而,癌症治疗仍然存在孤岛,直到今天,还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据,证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止,这些发现还没有转化为临床常规。在这个项目中,我们将开发技术增强和基于证据的以患者为中心的护理途径,称为MyPath,将其与肿瘤为中心的治疗相结合,包括支持性、姑息性、生存和临终关怀。在英国,我们已经在随机对照试验的背景下,在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的,并证明了临床医生在与所有患者交谈时使用简单,一致和清晰的语言,可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究,但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂,应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果,并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下,我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性,减少临床实践中的变化,并优化家庭、社区和医院护理环境中的资源。这将最终减轻与癌症相关的身体、情感和经济负担。在欧盟,2020年有270万人被诊断出患有癌症,130万人死于癌症。由于早期检测和新疗法的进步,超过1200万人从癌症中幸存下来。随着治愈率的提高和癌症患者寿命的延长,获得以患者为中心的护理,包括最佳支持、姑息治疗、生存和临终关怀,变得越来越重要。然而,癌症治疗仍然存在孤岛,直到今天,还没有适合不同文化、环境和环境的技术支持。一些随机对照试验提供了证据,证明在标准肿瘤治疗中整合以患者为中心的治疗可以改善患者和护理人员的预后。到目前为止,这些发现还没有转化为临床常规。在这个项目中,我们将开发技术增强和基于证据的以患者为中心的护理途径,称为MyPath,将其与肿瘤为中心的治疗相结合,包括支持性、姑息性、生存和临终关怀。在英国,我们已经在随机对照试验的背景下,在19个区域癌症中心整合了癌症疼痛评估和管理途径的经验。这一结果是积极的,并证明了临床医生在与所有患者交谈时使用简单,一致和清晰的语言,可以以非常积极的方式改变护理。虽然MyPath是一项复杂的研究,但我们的目标是通过简单、一致和清晰的途径实现的目标一点也不复杂,应该会大大改善癌症患者的护理和护理公平性。MyPath整合了us Eir软件的患者报告结果,并在欧洲知名肿瘤学家、伦理学家、心理学家和社会学家的贡献下进一步发展。它将在我们的中小企业合作伙伴DNV Imatis的eHealth平台上配置。它的有效性和可持续性将在欧洲9个临床中心的实施科学研究中进行评估。在领先的癌症护理专业协会ESMO和EAPC以及癌症患者组织ECPC的支持下,我们致力于在合适的时间由合适的人向合适的人提供合适的护理。我们假设MyPath可以显著提高治疗和护理的质量和可及性,减少临床实践中的变化,并优化家庭、社区和医院护理环境中的资源。这将最终减少与癌症相关的身体、情感和经济负担

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

其他文献

吉治仁志 他: "トランスジェニックマウスによるTIMP-1の線維化促進機序"最新医学. 55. 1781-1787 (2000)
Hitoshi Yoshiji 等:“转基因小鼠中 TIMP-1 的促纤维化机制”现代医学 55. 1781-1787 (2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
LiDAR Implementations for Autonomous Vehicle Applications
  • DOI:
  • 发表时间:
    2021
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
生命分子工学・海洋生命工学研究室
生物分子工程/海洋生物技术实验室
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
吉治仁志 他: "イラスト医学&サイエンスシリーズ血管の分子医学"羊土社(渋谷正史編). 125 (2000)
Hitoshi Yoshiji 等人:“血管医学与科学系列分子医学图解”Yodosha(涉谷正志编辑)125(2000)。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
Effect of manidipine hydrochloride,a calcium antagonist,on isoproterenol-induced left ventricular hypertrophy: "Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,K.,Teragaki,M.,Iwao,H.and Yoshikawa,J." Jpn Circ J. 62(1). 47-52 (1998)
钙拮抗剂盐酸马尼地平对异丙肾上腺素引起的左心室肥厚的影响:“Yoshiyama,M.,Takeuchi,K.,Kim,S.,Hanatani,A.,Omura,T.,Toda,I.,Akioka,
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:

的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('', 18)}}的其他基金

An implantable biosensor microsystem for real-time measurement of circulating biomarkers
用于实时测量循环生物标志物的植入式生物传感器微系统
  • 批准号:
    2901954
  • 财政年份:
    2028
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Exploiting the polysaccharide breakdown capacity of the human gut microbiome to develop environmentally sustainable dishwashing solutions
利用人类肠道微生物群的多糖分解能力来开发环境可持续的洗碗解决方案
  • 批准号:
    2896097
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
A Robot that Swims Through Granular Materials
可以在颗粒材料中游动的机器人
  • 批准号:
    2780268
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Likelihood and impact of severe space weather events on the resilience of nuclear power and safeguards monitoring.
严重空间天气事件对核电和保障监督的恢复力的可能性和影响。
  • 批准号:
    2908918
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Proton, alpha and gamma irradiation assisted stress corrosion cracking: understanding the fuel-stainless steel interface
质子、α 和 γ 辐照辅助应力腐蚀开裂:了解燃料-不锈钢界面
  • 批准号:
    2908693
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Field Assisted Sintering of Nuclear Fuel Simulants
核燃料模拟物的现场辅助烧结
  • 批准号:
    2908917
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Assessment of new fatigue capable titanium alloys for aerospace applications
评估用于航空航天应用的新型抗疲劳钛合金
  • 批准号:
    2879438
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Developing a 3D printed skin model using a Dextran - Collagen hydrogel to analyse the cellular and epigenetic effects of interleukin-17 inhibitors in
使用右旋糖酐-胶原蛋白水凝胶开发 3D 打印皮肤模型,以分析白细胞介素 17 抑制剂的细胞和表观遗传效应
  • 批准号:
    2890513
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
CDT year 1 so TBC in Oct 2024
CDT 第 1 年,预计 2024 年 10 月
  • 批准号:
    2879865
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Understanding the interplay between the gut microbiome, behavior and urbanisation in wild birds
了解野生鸟类肠道微生物组、行为和城市化之间的相互作用
  • 批准号:
    2876993
  • 财政年份:
    2027
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship

相似海外基金

Developing and Implementing Case-Based Scenarios to Support Elementary Pre-service Teachers’ Enactment of Equitable Mathematics and Science Instruction
制定和实施基于案例的方案以支持初级职前教师 — 制定公平的数学和科学教学
  • 批准号:
    2142136
  • 财政年份:
    2023
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Standard Grant
Listening to Patient Partners - From developing evidence-based tools for advancing meaningful patient engagement in research to now implementing them at an international organization for rheumatology research
倾听患者合作伙伴的意见 - 从开发基于证据的工具以促进患者有意义地参与研究,到现在在国际风湿病学研究组织中实施这些工具
  • 批准号:
    485116
  • 财政年份:
    2023
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Operating Grants
Developing, Validating, and Implementing an Epidemiological Instrument to Assess the Effect of Resistance Training on Measures of Cardiometabolic Disease
开发、验证和实施流行病学工具来评估阻力训练对心脏代谢疾病测量的影响
  • 批准号:
    10644525
  • 财政年份:
    2023
  • 资助金额:
    $ 70.31万
  • 项目类别:
Developing a pragmatic guide to implementing social risk referrals: A partnership between Caring Health Center (CHC) and the Implementation Science Center for Cancer
制定实施社会风险转诊的实用指南:关爱健康中心 (CHC) 与癌症实施科学中心之间的合作伙伴关系
  • 批准号:
    10822141
  • 财政年份:
    2023
  • 资助金额:
    $ 70.31万
  • 项目类别:
Developing and implementing tools to advance precision psychiatry using electronic health records
开发和实施工具,利用电子健康记录推进精准精神病学
  • 批准号:
    2886557
  • 财政年份:
    2023
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Studentship
Building Leadership among Science Teachers in Rural Regions: Designing, Developing, and Implementing a Science Teacher Leadership Academy
建设农村地区科学教师的领导力:设计、开发和实施科学教师领导力学院
  • 批准号:
    2243496
  • 财政年份:
    2023
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Continuing Grant
Developing, Implementing, and Pilot Testing an Informed Decision Aid for Opioid Agonist Therapies for Prisoners in Ukraine
为乌克兰囚犯开发、实施和试点测试阿片类药物激动剂疗法的知情决策辅助工具
  • 批准号:
    10531558
  • 财政年份:
    2022
  • 资助金额:
    $ 70.31万
  • 项目类别:
MyPath: Developing and implementing innovative Patient-Centred Care Pathways for cancer patients
MyPath:为癌症患者开发和实施以患者为中心的创新护理途径
  • 批准号:
    10039296
  • 财政年份:
    2022
  • 资助金额:
    $ 70.31万
  • 项目类别:
    EU-Funded
Developing a policy framework for implementing exercise therapy as standard of care for Nova Scotian's living with a cancer diagnosis
制定政策框架,将运动疗法作为新斯科舍省癌症诊断患者的护理标准
  • 批准号:
    465748
  • 财政年份:
    2022
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Fellowship Programs
Developing and implementing a standardized team-based approach to treat cardiogenic shock across Atlantic Canada
制定并实施基于团队的标准化方法来治疗加拿大大西洋地区的心源性休克
  • 批准号:
    460739
  • 财政年份:
    2022
  • 资助金额:
    $ 70.31万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了